Reticular Skin Rash as an Adverse Effect of 5-Azacitidine

Azacitidine is a hypomethylating agent used for the treatment of patients with myelodysplastic syndrome (MDS). It has been approved by the Food and Drug Administration (FDA) and the European Medicines Agency for the treatment of MDS and is also indicated for the treatment of acute myeloid leukemia (...

Descripción completa

Detalles Bibliográficos
Autores principales: Verma, Parul, Chandra, Usha, Shukla, Prakriti, Verma, Shailendra P, Suvirya, Swastika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Dermatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9117846/
https://www.ncbi.nlm.nih.gov/pubmed/35602804
http://dx.doi.org/10.7759/cureus.24228
Descripción
Sumario:Azacitidine is a hypomethylating agent used for the treatment of patients with myelodysplastic syndrome (MDS). It has been approved by the Food and Drug Administration (FDA) and the European Medicines Agency for the treatment of MDS and is also indicated for the treatment of acute myeloid leukemia (AML). Injection site erythema, ecchymosis, and petechiae are some of the common cutaneous adverse reactions associated with azacitidine. This article describes a rare adverse cutaneous drug reaction with azacitidine in the form of a reticular generalized skin rash in a 28-year-old female with AML.

Ejemplares similares